Guardant Health, Inc. (GH)

NMS – Real vaqt narxi. Valyuta: USD

99.94

+3.23 (3.34%)

Yopilishda: May 12, 2026, 4:00 PM EDT

102.90

+2.96 (2.96%)

Bozor oldidan: May 13, 2026, 5:19 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Guardant Health, Inc. (GH)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Guardant Health, Inc. (GH)

Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript

Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics

Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates

Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

Brown Advisory Sustainable Small-Cap Core Strategy Q1 2026 Portfolio Activity

Videolar

Press-relizlar

Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

Search stocks

Guardant Health, Inc. (GH)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Guardant Health, Inc. (GH)

Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript

Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics

Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates

Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

Brown Advisory Sustainable Small-Cap Core Strategy Q1 2026 Portfolio Activity

Videolar

Press-relizlar

Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan